ICE Bioscience develops drug-resistant cancer cell line models through both continuous or stepwise drug exposure and gene-editing-based model generation. Our current focus is on building ADC/payload-resistant and RAS pathway–associated resistant cell line models and screening platforms, while also supporting customized resistant model development and profiling for other target and mechanism areas.
Resistant sublines developed against payload classes such as topoisomerase I inhibitors or tubulin inhibitors, enabling cross-resistance evaluation and strategy development for ADC programs.
Resistant sublines induced by prolonged exposure to RAS inhibitors to support pathway adaptation studies and rational combination exploration.
Add-ons may include transporter overexpression checks such as ABCG2 or ABCB1, target/pathway markers, and transcriptomic comparison between parental and resistant lines.
This case study uses matched parental and ADC/payload-resistant HCC1806 models to identify cross-resistance patterns and resistant-cell selective vulnerabilities through approved drug library screening.
This application note highlights how resistant cell models can support mechanism-oriented interpretation beyond target expression, using an NCI-N87 DS-8201 resistance model as the case example.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
